Aachen, Germany & Yeoju, South Korea (OTE) – Grünenthal, a global
leader in pain management and related diseases,
and BCWorld Pharm Co., Ltd. („BCWP“), a specialty company actively
expanding and diversifying its pain management portfolio through
global open innovation partnerships, announced today that they have
entered into a definitive agreement whereby BCWP will have the
exclusive South Korean rights to Qutenza®, a topical, non-systemic,
non-opioid patch treatment. In Europe, the product is indicated for
the management of peripheral neuropathic pain.
Under the agreement, BCWP will be responsible for obtaining
marketing authorisation for Qutenza® in South Korea. Upon approval,
the company will market and distribute the product. Grünenthal will
receive an upfront payment in addition to regulatory and sales-
related milestone payments.
“We are executing on a dedicated strategy to bring Qutenza® into
the Asia-Pacific region to facilitate greater access to non-opioid
treatment options for people living with pain and expand the brand’s
global footprint,” says Jan Adams, Chief Commercial Officer (CCO) at
Grünenthal. “With BCWP, we have a strong speciality care partner in
South Korea, a major market in the Asia-Pacific region, and we are
pleased to expand our existing partnership to further progress
towards our vision of a World Free of Pain.”
“Expanding access to innovative, non-opioid treatment options for
patients with neuropathic pain is central to our mission of ‘Commit
to a Better Future for Patients’,” says Steve Hong, CEO of BCWorld
Pharm. “Our partnership with Grünenthal enables us to introduce
Qutenza® to South Korea while further diversifying and strengthening
our pain management portfolio.” Grünenthal acquired the global rights
to Qutenza® in 2018 as part of its M&A-driven growth strategy. Since
2017, Grünenthal has closed successful acquisitions with a total
expected deal value of more than Ꞓ2.3 billion, diversifying its
portfolio, enhancing its profitability, and driving business growth.
Grünenthal continues to expand the footprint of the acquired brands
and to create synergies throughout Grünenthal’s infrastructure,
including manufacturing, supply, logistics, and commercial
activities.
About Qutenza®
In Europe, Qutenzais indicated for the treatment of peripheral
neuropathic pain in adults, either alone or in combination with other
medicinal products for the treatment of pain. For further
information, please visit www.grunenthalhealth.com .Qutenza (
capsaicin) 8% topical system is approved in the US for the treatment
of neuropathic pain associated with postherpetic neuralgia and for
the treatment of neuropathic pain associated with diabetic peripheral
neuropathy (DPN) of the feet in adults. Important US safety
information is available at www.qutenza.com .
About Grünenthal Grünenthal is a global leader in pain management
and related diseases. As a science-based, fully integrated
pharmaceutical company, we have a long track record of bringing
innovative treatments and state-of-the-art technologies to patients
worldwide. Our purpose is to change lives for the better – and
innovation is our passion. We focus all our activities and efforts on
working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has
affiliates in 28 countries across Europe, Latin America, and the U.S.
Our products are available in approx. 100 countries. In 2024,
Grünenthal employed around 4,300 people and achieved revenues of Ꞓ1.8
billion.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group | Instagram: grunenthal
About BCWorldPharm
BCWorld Pharm Co., Ltd. is a KOSDAQ-listed South Korean specialty
pharmaceutical company with a strong presence in the domestic pain
market. The company is expanding its portfolio through global
partnerships, including its recently expanded collaboration on
Nucynta®. Under its Vision 2030 strategy, BCWorld Pharm aims to
strengthen its leadership in specialty pain care in Korea and
beyond.”
More information: www.bcwp.co.kr/eng/
Digital press kit: http://www.ots.at/pressemappe/DE118252/aom
